Similar articles

• Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: CHRONICLE. A randomised phase III trial of control vs. capecitabine plus oxaliplatin.

  Glynne-Jones R, Meadows H, Wood W. Glynne-Jones R, et al. Clin Oncol (R Coll Radiol). 2007 Jun;19(5):327-9. doi: 10.1016/j.clon.2007.03.003. Epub 2007 Apr 16. Clin Oncol (R Coll Radiol). 2007. PMID: 17434299 No abstract available.
• [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].

  Suzuki S, Shigaki N, Yokoyama S, Yamashita H, Sugita H, Arima N. Suzuki S, et al. Gan To Kagaku Ryoho. 2011 Sep;38(9):1545-7. Gan To Kagaku Ryoho. 2011. PMID: 21918360 Japanese.
• Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.

  Flatmark K, Ree AH. Flatmark K, et al. J Clin Oncol. 2010 Oct 10;28(29):e577-8; author reply e581-3. doi: 10.1200/JCO.2010.30.0921. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733124 No abstract available.
• Combined-modality therapy for rectal cancer: future prospects.

  Czito BG, Willett CG, Bendell JC. Czito BG, et al. Clin Colorectal Cancer. 2007 Sep;6(9):625-33. doi: 10.3816/CCC.2007.n.030. Clin Colorectal Cancer. 2007. PMID: 17945034 Review.
• [Difference of colon cancer and rectal cancer-from the view of an oncological physician].

  Xu JM. Xu JM. Zhonghua Zhong Liu Za Zhi. 2010 May;32(5):321-3. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 20723426 Review. Chinese. No abstract available.